Click Here to
News, Updates,
& More
Stay Up
to Date

Ovarian Cancer

Ovarian cancer not only exacts a high mortality rate, but also affects the physical, mental, and financial health of those diagnosed with the disease.
Epidemiologic studies reveal population-based disparities in ovarian cancer morbidity and mortality rates.
Genetic, menstrual, and other factors have been associated with increased risk of ovarian cancer.
Current screening practices for ovarian cancer continue to result in late-stage diagnoses with consequent poor prognoses.

On October 23, 2019, the FDA approved the PARP inhibitor niraparib (Zejula; Tesaro) for the treatment of patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer, after ≥3 chemotherapy regimens. HRD is defined by a deleterious or suspected deleterious BRCA mutation, or a genomic instability associated with disease progression >6 months after the tumor’s response to the last platinum-based chemotherapy. On the same day, the FDA also approved the Myriad myChoice CDx test to select patients for niraparib therapy based on the HRD tumor status.

  • Zejula Now Approved for Late-Line Ovarian Cancer
  • Trump Set to Nominate Hahn as FDA Commissioner
  • FDA Aims to Improve Breast Implant Guidance
In ovarian epithelial cancer, fallopian tube cancer, and primary peritoneal cancer, malignant cells form in the tissue covering the ovary or lining the fallopian tube or peritoneum. According to the American Cancer Society, in 2017 more than 22,000 women in the United States were estimated to be diagnosed with these cancers and more than 14,000 to die from them.

Results 1 - 7 of 7